



PI : Prof. Tur-Fu Huang

Department of Pharmacology College of Medicine, National Taiwan U.

**Experience:**

<http://pharmacology.ntu.edu.tw/main/Tur-Fu%20Huang/PAGE01.HTM>

**Market Needs:**

- anti-asthma drugs
- anti-platelet and anti-thrombosis
- anti-atherosclerosis, anti-restenosis and anti-embolic stroke
- thromboxane A2 overproduction-related diseases

**Our Technology:**

1. A novel thromboxane receptor antagonist, nstpbp5185, inhibits platelet aggregation and thrombus formation in animal models. (Thromb Haemost. 116(2):285-299)
2. Oral TP-receptor antagonist, nstpbp5185, attenuates atherosclerotic progression in Apo E-deficient mice.
3. The benzimidazole derivative, nstpbp5185, attenuates the inflammatory response and improves survival in murine sepsis models.
4. Nstpbp5185 attenuates the progression of neointima formation in a rat model of balloon injury.
5. Antiasthmatic effects of thromboxane A2 receptor antagonist, nstpbp5185, in ovalbumin-induced asthma model mice.

**Strength:**

Orally-active TP antagonist

**Competing Products:**

- Seratrodast (AA-2414, Bronica®)
- Ozagrel hydrochloride (OKY-046, Ozagrel®)
- Ramatroban (BAY-U-3405, Baynas®)
- EV-077 (Evolva)

**Intellectual Properties:**

1. Rhodostomin 抑制人體血小板凝集之多肽(1991/01 to 2006/12) (R.O.C.49660)
2. DISINTEGRIN VARIANTS AND PHARMACEUTICAL USES THEREOF (2009/08 to 2015/07)(USA:ANC104 77P000 30US)
3. PEPTIDE COMPOUNDS FOR INHIBITION OF PLATELET AGGREGATION (2013/12/16~) (USA: 14/126,808) °
4. A novel Alpha IIb Beta 3 antagonist TMV-7 inhibits thrombotic embolism without causing pathological bleeding. USA provisional patent: 62/216,362 (2015/09/10)

**Contact (do not need to fill out):**

Center for Industry-Academia Cooperation, NTU

Tel: 02-3366-9945, E-mail: [ntuciac@ntu.edu.tw](mailto:ntuciac@ntu.edu.tw)

This information herein is intended for potential license of NTU technology only. Other usage of all or portion of this information in whatever form or means is strictly prohibited. Kindly contact us and we will help to achieve your goal the best we can.